• InflaRx NV focus on immune therapies as investors weigh long-term prospects AD HOC NEWS Tue, 07 Jul 2026 17:38:12 GMT
• In wake of Tavneos setback, developer working on 2 new vasculitis treaments ANCA Vasculitis News Wed, 01 Jul 2026 22:41:16 GMT
• InflaRx seeks to fill void left by Amgen’s Tavneos in Europe European Biotechnology Magazine Wed, 01 Jul 2026 07:37:47 GMT
• InflaRx Moves to Broaden AAV Strategy in Europe After EMA Setback for Tavneos TipRanks Tue, 30 Jun 2026 20:38:28 GMT
• InflaRx (IFRX) rethinks European AAV path after EMA Tavneos setback Stock Titan Tue, 30 Jun 2026 20:06:00 GMT
• InflaRx to Engage EMA on Vilobelimab and Izicopan Development Path in AAV Quiver Quantitative Tue, 30 Jun 2026 11:41:00 GMT
• InflaRx to explore regulatory path for AAV drugs in Europe By Investing.com Investing.com Canada Tue, 30 Jun 2026 11:39:21 GMT
• EMA move on Tavneos pushes InflaRx to widen AAV plan in Europe Stock Titan Tue, 30 Jun 2026 11:30:00 GMT
• inflarx assessing feasibility of broadened strategy for GlobeNewswire Tue, 30 Jun 2026 11:30:00 GMT
• Guggenheim Maintains InflaRx(IFRX.US) With Buy Rating, Maintains Target Price $14 Moomoo Thu, 25 Jun 2026 15:23:52 GMT
• inflarx nv (ifrx) technical analysis: support, resistance, indicators & moving averages TradingKey Mon, 22 Jun 2026 07:00:00 GMT
• inflarx nv (ifrx) technical analysis: support, resistance, indicators & moving averages TradingKey Thu, 18 Jun 2026 12:30:10 GMT
• inflarx nv (ifrx) revenue breakdown: business segments, regional revenue & profit contribution TradingKey Thu, 18 Jun 2026 06:47:20 GMT
• inflarx nv (ifrx) financial health: profitability & balance sheet analysis TradingKey Thu, 18 Jun 2026 05:44:27 GMT
• inflarx nv (ifrx) risk assessment: volatility, financial risk & investment risk TradingKey Thu, 18 Jun 2026 01:40:26 GMT
• inflarx nv (ifrx) dividends & stock splits: historical payouts and event timeline TradingKey Wed, 17 Jun 2026 21:53:22 GMT
• inflarx nv (ifrx) shareholder structure: major shareholders & institutional holdings TradingKey Wed, 17 Jun 2026 21:51:32 GMT
• inflarx nv (ifrx) earnings forecast: future eps & revenue growth estimates TradingKey Wed, 17 Jun 2026 20:12:56 GMT
• inflarx nv (ifrx) valuation: pe, pb & fair value analysis TradingKey Wed, 17 Jun 2026 17:22:07 GMT
• inflarx nv (ifrx) technical analysis: support, resistance, indicators & moving averages TradingKey Wed, 17 Jun 2026 07:00:00 GMT
• ifrx q1 2026 earnings: narrower-than-expected loss signals cost discipline, though stock declines - strong earnings momentum newsline.com Tue, 16 Jun 2026 16:40:46 GMT
• inflarx nv (ifrx) earnings forecast: future eps & revenue growth estimates TradingKey Mon, 15 Jun 2026 07:00:00 GMT
• inflarx n.v. q1 2026 earnings: narrower-than-expected loss despite stock decline - eps revision trend newsline.com Sun, 14 Jun 2026 16:36:05 GMT
• ifrx q1 2026 earnings: narrower-than-expected loss amid clinical progress; stock slips - net income trends newsline.com Sat, 13 Jun 2026 01:36:02 GMT
• IFRX Q1 2026 Earnings: Narrower-than-Expected Loss Amid Clinical Progress; Stock Slips - EPS Consistency Score dars.gov.et Fri, 12 Jun 2026 07:00:00 GMT
• inflarx n.v. (ifrx) q1 2026 earnings: eps exceeds expectations as drug development advances newsline.com Wed, 10 Jun 2026 06:34:37 GMT
• IFRX Q4 2025 Earnings: Narrower-than-Expected Loss Fails to Stem Stock Decline - Long-Term Guidance dars.gov.et Sat, 06 Jun 2026 07:00:00 GMT
• inflarx prices $150 million share offering at $2 per share Investing.com Sat, 06 Jun 2026 02:06:36 GMT
• inflarx prices $150 million share offering at $2 per share by investing.com Investing.com Australia Fri, 05 Jun 2026 13:30:15 GMT
• inflarx stock surges on aav drug development plan by investing.com Investing.com Nigeria Fri, 05 Jun 2026 07:00:00 GMT
• inflarx to develop izicopan for kidney disease treatment Investing.com Fri, 05 Jun 2026 07:00:00 GMT
• inflarx prices $150 million share offering at $2 per share by investing.com Investing.com Australia Thu, 04 Jun 2026 12:09:16 GMT
• inflarx investor update: izicopan set to take center stage in aav and renal disease pipeline MSN Wed, 03 Jun 2026 05:14:37 GMT
• inflarx nv stock (nl0012661870): nasdaq-listed biotech trades lower ahead of next earnings update Ad-hoc-news.de Tue, 02 Jun 2026 07:00:00 GMT
• IFRX Q4 2025 Earnings: Narrower-Than-Expected Loss Despite Revenue Absence - Pre-Announcement Alert dars.gov.et Mon, 01 Jun 2026 07:00:00 GMT
• Here’s Why InflaRx (IFRX) is Among the 10 Most Volatile Penny Stocks to Buy Now Yahoo Finance Sun, 31 May 2026 07:00:00 GMT
• inflarx n.v. (ifrx) edges higher with modest gains, tests key resistance zone - etf nav deviation newsline.com Sun, 31 May 2026 07:00:00 GMT
• InflaRx N.V. Shows Resilience: IFRX Stock Edges Higher on Modest Volume - McClellan Summation dars.gov.et Fri, 29 May 2026 07:00:00 GMT
• ifrx stock price, quote & chart | inflarx nv (nasdaq:ifrx) ChartMill Fri, 29 May 2026 07:00:00 GMT
• ifrx technical analysis | trend, signals & chart patterns | inflarx nv (nasdaq:ifrx) ChartMill Fri, 29 May 2026 07:00:00 GMT
• inflarx n.v. (ifrx) tumbles 7% as shares test key support levels - smart beta flow newsline.com Thu, 28 May 2026 07:00:00 GMT
• inflarx prices $150 million share offering at $2 per share by investing.com Investing.com Nigeria Wed, 27 May 2026 12:55:10 GMT
• inflarx (ifrx) surges nearly 5%, testing key resistance at $2.88 - equal weight etf newsline.com Tue, 26 May 2026 07:00:00 GMT
• inflarx investor update: izicopan set to take center stage in aav and renal disease pipeline MSN Sun, 24 May 2026 23:33:49 GMT
• InflaRx (IFRX) Q4 2025 Earnings: Slight EPS Beat Amid Pre‑Revenue Phase - Guidance Update dars.gov.et Sun, 24 May 2026 07:00:00 GMT
• inflarx (ifrx) surges 6.5% as stock tests key resistance - put call ratio dars.gov.et Fri, 22 May 2026 07:00:00 GMT
• inflarx investor update: izicopan set to take center stage in aav and renal disease pipeline MSN Thu, 21 May 2026 16:15:21 GMT
• inflarx nv stock (nl0012661870): what’s behind the latest trading volatility after gohibic’s slo AD HOC NEWS Tue, 19 May 2026 07:00:00 GMT
• raymond james maintains inflarx(ifrx.us) with buy rating, maintains target price $9 富途牛牛 Tue, 19 May 2026 02:15:15 GMT
• inflarx to develop izicopan for kidney disease treatment by investing.com Investing.com Nigeria Mon, 18 May 2026 18:56:42 GMT
• ifrx technical analysis | trend, signals & chart patterns | inflarx nv (nasdaq:ifrx) ChartMill Mon, 18 May 2026 07:00:00 GMT
• inflarx investor update: izicopan set to take center stage in aav and renal disease pipeline MSN Sun, 17 May 2026 11:46:16 GMT
• inflarx nv stock (nl0012661870): may data from a recent ytd ranking AD HOC NEWS Sat, 16 May 2026 07:00:00 GMT
• Farallon funds and managers report shared stakes in InflaRx (IFRX) Stock Titan Thu, 14 May 2026 07:00:00 GMT
• inflarx upgraded to strong buy from outperform at raymond james TipRanks Wed, 13 May 2026 17:29:15 GMT
• inflarx nv stock (ifrx): favorable izicopan data released AD HOC NEWS Wed, 13 May 2026 12:45:55 GMT
• raymond james maintains inflarx(ifrx.us) with buy rating, maintains target price $9 Moomoo Wed, 13 May 2026 12:34:00 GMT
• Inflarx stock upgraded to Strong Buy at Raymond James on drug potential Investing.com Wed, 13 May 2026 07:00:00 GMT
• inflarx investor update: izicopan set to take center stage in aav and renal disease pipeline MSN Wed, 13 May 2026 04:49:05 GMT
• [schedule 13g] inflarx n.v. passive investment disclosure (>5%) Stock Titan Tue, 12 May 2026 22:03:13 GMT
• h.c. wainwright maintains inflarx(ifrx.us) with buy rating, maintains target price $8 Moomoo Tue, 12 May 2026 18:31:00 GMT
• TCG Crossover III and Chen Yu disclose 9.8% stake in InflaRx (IFRX) Stock Titan Tue, 12 May 2026 07:00:00 GMT
• inflarx nv stock (nl0012661870): hc wainwright raises price target to $8 AD HOC NEWS Tue, 12 May 2026 07:00:00 GMT
• Phase 2 trial planned to test oral therapy izicopan in AAV ANCA Vasculitis News Mon, 11 May 2026 07:00:00 GMT
• h.c. wainwright maintains inflarx(ifrx.us) with buy rating, raises target price to $8 Moomoo Mon, 11 May 2026 07:00:00 GMT
• inflarx investor update: izicopan set to take center stage in aav and renal disease pipeline MSN Sun, 10 May 2026 02:04:25 GMT
• inflarx investor update: izicopan set to take center stage in aav and renal disease pipeline MSN Sat, 09 May 2026 06:54:27 GMT
• inflarx | 6-k: report of foreign private issuer (related to financial reporting) Moomoo Fri, 08 May 2026 07:12:44 GMT
• InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares GlobeNewswire Fri, 08 May 2026 07:00:00 GMT
• 75 million new InflaRx shares raise cash to fund drug pipeline Stock Titan Fri, 08 May 2026 07:00:00 GMT
• InflaRx Unveils Izicopan Strategic Shift And $150m Offering insights.citeline.com Fri, 08 May 2026 07:00:00 GMT
• InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline Yahoo Finance Fri, 08 May 2026 07:00:00 GMT
• InflaRx N.V. (IFRX) Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases - Slideshow (NASDAQ:IF... Seeking Alpha Fri, 08 May 2026 07:00:00 GMT
• inflarx n.v. completes $150 million underwritten offering of ordinary shares to advance pipeline activities Quiver Quantitative Fri, 08 May 2026 07:00:00 GMT
• inflarx doubles its share count to secure $150 million war chest for kidney drug push Ad-hoc-news.de Fri, 08 May 2026 07:00:00 GMT
• inflarx completes $150 million stock offering at $2 per share by investing.com Investing.com Canada Fri, 08 May 2026 07:00:00 GMT
• inflarx raises $150 million in underwritten share offering filed in early may 2026 The Globe and Mail Fri, 08 May 2026 07:00:00 GMT
• inflarx | 6-k: report of foreign private issuer (related to financial reporting) Moomoo Thu, 07 May 2026 21:40:37 GMT
• InflaRx attracts strong investor interest with US share offering turning to kidney European Biotechnology Magazine Thu, 07 May 2026 07:00:00 GMT
• InflaRx (NASDAQ: IFRX) raises $150M in underwritten share sale Stock Titan Thu, 07 May 2026 07:00:00 GMT
• inflarx banks $150 million to fund kidney disease pivot after covid drug retreat AD HOC NEWS Thu, 07 May 2026 07:00:00 GMT
• inflarx prices $150m stock sale to fund pipeline and working capital Stock Titan Thu, 07 May 2026 07:00:00 GMT
• inflarx stock surges on aav drug development plan by investing.com Investing.com Australia Thu, 07 May 2026 07:00:00 GMT
• inflarx (nasdaq: ifrx) raises $150m via 75m-share offering to fund izicopan Stock Titan Thu, 07 May 2026 07:00:00 GMT
• inflarx raises $150 million in underwritten share offering filed in early may 2026 TipRanks Thu, 07 May 2026 07:00:00 GMT
• inflarx pulls off $150 million capital raise as pipeline pivot gathers pace AD HOC NEWS Wed, 06 May 2026 22:50:41 GMT
• inflarx nv files for offerng of ordinary shares, size not disclosed - sec filing TradingView Wed, 06 May 2026 21:11:41 GMT
• [424b5] inflarx n.v. prospectus supplement (debt securities) Stock Titan Wed, 06 May 2026 20:01:35 GMT
• inflarx prices $150 million underwritten share offering The Pharma Letter Wed, 06 May 2026 16:24:50 GMT
• inflarx | 6-k: report of foreign private issuer [rules 13a-16 and 15d-16] Moomoo Wed, 06 May 2026 14:41:10 GMT
• InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases GlobeNewswire Wed, 06 May 2026 07:00:00 GMT
• InflaRx prices $150M stock sale to fund pipeline and working capital Stock Titan Wed, 06 May 2026 07:00:00 GMT
• InflaRx to develop izicopan for kidney disease treatment Investing.com Wed, 06 May 2026 07:00:00 GMT
• Funded through 2029, InflaRx expands izicopan into kidney diseases Stock Titan Wed, 06 May 2026 07:00:00 GMT
• InflaRx prices $150 million share offering at $2 per share By Investing.com Investing.com Canada Wed, 06 May 2026 07:00:00 GMT
• InflaRx Refocuses Izicopan on Vasculitis and Renal Diseases With Funding Runway to 2029 TipRanks Wed, 06 May 2026 07:00:00 GMT
• inflarx advances development of izicopan for anca-associated vasculitis and broader renal diseases with upcoming capital markets d... Quiver Quantitative Wed, 06 May 2026 07:00:00 GMT
InflaRx N.V(NASDAQ:IFRX) 
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company...
Website: http://www.inflarx.de
Founded: 2018
Full Time Employees: 43
Sector: Healthcare
Industry: Biotechnology